Tierney Junker (tvbra7)
SGLT-2i separately. Registration URL https//www.clinicaltrials.gov. Unique identifier NCT03878706.Innate immune activation has been attributed a key role in traumatic brain injury (TBI) and successive morbidity. In mild TBI, however, the extent and persistence of innate immune activation are unknown. We aimed to determine plasma cytokine level (1) changes over 12-months after a mild TBI in hospitalized and non-hospitalized patients compared to community controls; and (2) associations to injury-related and demographic variables at admission. Prospectively, 207 patients presenting to the emergency department or general practitioner with clinically confirmed mild TBI and 82 matched community controls were included. Plasma samples were obtained at admission, after 2 weeks, 3 and 12 months. Cytokine levels were analysed with a 27-plex beads-based immunoassay. Brain MRI was performed on all participants. Twelve cytokines were reliably detected. Plasma levels of IFN-, IL-8, eotaxin, MIP-1, MCP-1, IL-17A, IL-9, TNF, and FGF basic were significantly increased at all timepoints in patients compared to controls, while IP-10, PDGF, and IL-1RA were not. IL-17A and FGF-basic showed significant increases in patients from admission to follow-up at 3 months, and remained elevated at 12 months compared to admission. Interestingly, MRI findings were negatively associated with four cytokines eotaxin, MIP-1, IL-9 and IP-10, while age was positively associated with nine cytokines IL-8, eotaxin, MIP-1, MCP-1,IL-17A, IL-9, TNF, FGF-basic and IL-1ra. this website TNF was also elevated in those with presence of other injuries. In conclusion, mild TBI activated the innate immune system consistently and this is the first study to show that several inflammatory cytokines remain elevated for up to one-year post-injury.Purpose This study examined health care providers' perceptions of the usefulness and ease of use of a symptom heuristics app delivered via a tablet computer as a resource for understanding symptom experiences of adolescents and young adults (AYAs) with cancer. AYAs' app-generated symptom reports were compared with providers' documentation of AYAs' symptoms. Methods This multisite study included responses from 86 AYAs 15-29 years of age who completed the Computerized Symptom Capture Tool (C-SCAT) before two scheduled visits for chemotherapy. After each visit, their providers completed a survey addressing their perspective of (1) the usefulness of data provided by the C-SCAT to understand the AYAs' symptom experience, and (2) the nature of the discussion of symptoms with the AYA. An electronic health record review compared symptoms that AYAs identified by using the C-SCAT with providers' documentation of symptoms. Results One hundred forty-four complete surveys were returned after 162 visits. Fifty percent (n = 72) of responses reported that the C-SCAT helped identify the patient's symptoms, and 53% (n = 76) reported that it helped identify the patient's priority symptoms. Providers also reported higher patient engagement and more focused discussions regarding symptoms. They reported that use of the C-SCAT facilitated the development of symptom management plans. Priority symptoms were documented more frequently than nonpriority symptoms (54% vs. 32.7%; p less then 0.01) as was a plan for managing priority symptoms (33.7% vs. 17.9%; p less then 0.01). Conclusion Use of the C-SCAT enhanced providers' understanding of AYAs' symptom experiences. Further research is needed to demonstrate the effectiveness of the C-SCAT as a resource to improve symptom management among AYAs with cancer.Background High prevalence of opioid misuse has been noted among youth and young adults-particularly among those who identify as lesbian/gay or bisexual (LGB). Yet, little is known about the relationship between opioid-related attitudes and misuse among those who identify as LGB. Objectives This study examined the role of opioid-related attitudes (i.e. ac
